Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Pharmacoeconomics|October 13, 2010
An analysis of NICE's 'restricted' (or 'optimized') decisionsPhill O'Neill, Nancy J DevlinPharmacoeconomics|July 13, 2026
Optimisation or Restriction? Unpacking the Logic Behind NICE DecisionsNadine Henderson, Brittany Darrow, Phill O'Neill, et al.Vaccine: X|May 17, 2021
Realising the broader value of vaccines in the UKSimon Brassel, Margherita Neri, Phill O'Neill, et al.Applied Health Economics and Health Policy|February 15, 2017
EQ-5D and the EuroQol Group: Past, Present and FutureNancy J Devlin, Richard BrooksThe European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 7, 2020
Does NICE influence the adoption and uptake of generics in the UK?Victoria Serra-Sastre, Simona Bianchi, Jorge Mestre-Ferrandiz, et al.Pharmacoeconomics|September 17, 2013
Projecting expenditure on medicines in the UK NHSPhill O'Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro, et al.Orphanet Journal of Rare Diseases|May 5, 2019
Comparing access to orphan medicinal products in EuropeBernarda Zamora, Francois Maignen, Phill O'Neill, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 2, 2013
Assessing the performance of the EQ-VAS in the NHS PROMs programmeYan Feng, David Parkin, Nancy J DevlinHealth Economics|July 13, 2010
Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D dataNancy J Devlin, David Parkin, John BrowneQuality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 12, 2004
Understanding health state valuations: a qualitative analysis of respondents' commentsNancy J Devlin, Paul Hansen, Caroline SelaiPageof 5